Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.

DHT is the primary cause of hair loss, but factors like diet, stress, and lifestyle can influence its severity. Treatments like finasteride and dutasteride target DHT, while maintaining overall health is also important.

DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.

A 23-year-old male saw significant hair improvement after using topical minoxidil for five years and oral finasteride for one year. He is considering adding dutasteride weekly and continues using Head & Shoulders and Stiproxal for dandruff control.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

Stopping finasteride and minoxidil can cause significant hair shedding, so they should be continued indefinitely. Concerns about finasteride affecting fertility or causing birth defects are mostly unfounded, but some stop for personal reasons.

A 49-year-old has used finasteride for 19 years to manage hair loss, experiencing some libido changes but no major side effects, and plans to continue. They found minoxidil inconvenient but are considering restarting it with micro-needling.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Hair loss challenges and identity issues, with opinions on using finasteride, minoxidil, and hair transplants versus accepting baldness. Some find shaving more work, while others stress personal choice and self-perception.

A user stopped finasteride after 15 years due to severe side effects, which improved after quitting. They maintained most of their hair and are considering alternatives like topical treatments or RU58841.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

A woman experienced significant hair regrowth after six months of using dutasteride and minoxidil, despite initial hair loss due to androgenetic alopecia. She reported minimal side effects and highlighted the effectiveness of these treatments for women, despite doctors' hesitancy to prescribe them.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

Microneedling with minoxidil significantly boosts hair growth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.

Effective treatments for hair loss include finasteride, dutasteride, RU58841, and minoxidil. Starting treatment early is important, and users discuss different brands, forms, and side effects.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

A 20-year-old experiencing hair shedding after starting oral finasteride is advised to continue treatment and consider adding topical minoxidil. Shedding is normal, and patience is needed for hair regrowth.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

A 15-year-old experiencing hair loss and anxiety is using minoxidil and microneedling but is advised against starting finasteride or dutasteride due to age. The discussion emphasizes consulting a doctor, considering hormonal evaluations, and exploring non-medication coping strategies.

Starting finasteride earlier is generally more effective for hair loss, with no evidence of reduced effectiveness over time. Oral finasteride is recommended for better results, and starting treatment after age 18 is advised.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

The user stopped finasteride for three months to try for a baby but continued using minoxidil and micro-needling. They are concerned about hair shedding and plan to resume finasteride after the baby is born.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

An 18-year-old began using Finasteride and Topical Minoxidil for hair loss, later switching to Oral Minoxidil and Dutasteride by age 25. The conversation emphasizes early treatment, potential side effects, and differing opinions on medication effectiveness.

Minoxidil 5% topical solution may cause eyesight problems, with some users experiencing blurred vision. The discussion also mentions finasteride's potential side effects, including erectile dysfunction, with varied personal experiences.

Finasteride and dutasteride can improve skin texture and reduce acne by lowering DHT but do not reverse aging. They may enhance skin and hair health for some, but can also cause side effects like dry skin and sexual dysfunction.

Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

The user has been using finasteride for 18 years to manage hair loss and is considering starting minoxidil and possibly a hair transplant. Despite some regrowth, they are exploring additional treatments like dutasteride and oral minoxidil due to continued hair thinning.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.